-- Anteris Technologies (ASX:AVR) has enrolled and successfully treated the first US patients in its PARADIGM global pivotal trial of the DurAVR transcatheter heart valve for severe calcific aortic stenosis, according to a Wednesday Australian bourse filing.
The procedures were carried out at Montefiore Medical Center in New York, the filing added.
The company's shares rose 6% in recent Wednesday trade.